AlphAIalphai — Financial news for AI agents
prnewswire.comAUG 272 min read$ABBV

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

AbbVie (ABBV) submitted an application to the EMA for approval of SKYRIZI® (risankizumab) subcutaneous induction for treating adults with moderately to severely active Crohn's disease. The application is supported by positive Phase 3 AFFIRM study data. If approved, it will provide an additional treatment option for patients.

Original reporting
prnewswire.com
Published Aug 27, 2026, 6:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 7:28 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefRegulation
Primary signal
$ABBV
Bullish
high confidence
Mentioned
$ABBV
Relevance
8/10
alphai data visualization · based on prnewswire.com
Decision brief

The 30-second read

$ABBVBullishMed
01

Why it matters

Regulatory filing is a primary catalyst; market will price in probability of approval.

02

Market read

Potential expansion of SKYRIZI's label could boost AbbVie's revenue and affect the biotech sector.

03

What to watch

Pricing, reimbursement negotiations, and competition from other biologics could limit impact.

Relevance 8/10Novelty 8/10Timing: today

Background

AbbVie already markets SKYRIZI for several indications; this filing seeks a new subcutaneous induction route for Crohn's disease in the EU.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie submitted a new EMA application for SKYRIZI subcutaneous induction in Crohn's disease, a fresh regulatory filing.

Expected impact

moderate upside if approval granted; downside risk if rejected

Evidence & confidence

Regulatory approval is a key catalyst for biotech stocks; the submission indicates progress toward a new indication.

Market effects

Sector

May lift other IL-23 inhibitors and Crohn's disease therapeutics as a competitive benchmark.

Regional

European biotech sector could see increased investor interest.

Global

Adds to the pipeline narrative for major US pharma firms.

Counterpoint

What could challenge this read

Approval is uncertain; EMA may request additional data, delaying any upside.

Key entities

  • Company
    AbbVie

    Pharmaceutical company developing SKYRIZI.

  • Regulator
    European Medicines Agency (EMA)

    Authority reviewing the application.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 28
$ABBVMedAI 9/10

Has AbbVie Stock Become Too Expensive to Buy?

AbbVie (ABBV) stock has risen 25% in three months, near its 52-week high. The company reports strong financials, with a 34% operating margin and 10.4% revenue growth. However, its P/E ratio of 74.5 is high compared to the S&P 500 median of 23.5, raising concerns about valuation and future growth.

yahoo.com2 min
AUG 27
$ABBVMedAI 8/10

AbbVie Seeks EMA Nod For SKYRIZI Subcutaneous Induction In Crohn's Disease

AbbVie (ABBV) submitted a regulatory application to the European Medicines Agency for SKYRIZI subcutaneous induction in Crohn's disease. The application is based on positive Phase 3 AFFIRM study results, showing clinical remission and endoscopic response at week 12. If approved, patients could choose between SC injection or IV infusion for induction, followed by SC maintenance dosing. SKYRIZI is already approved for Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis.

rttnews.com2 min
AUG 26
$MRNAHighAI 9/10

Top Biopharma Analyst Sees Biotech M&A Market Reopening After a Long Freeze

Moderna (MRNA) and Merck (MRK) cancer vaccine reduced melanoma recurrence risk 49%, boosting MRNA +177% on readout. Revolution Medicines (RVMD) drug doubled pancreatic cancer survival, RVMD +163% YTD. AbbVie (ABBV) acquired Apogee for $10.9B. Barclays' Emily Field notes biotech M&A freeze is over, citing capital market reopening and oncology innovation.

yahoo.com3 min
AUG 24
$ABBVMedAI 8/10

AbbVie’s Humira Replacement Strategy Is Working, But Could Growth Be Too Concentrated?

AbbVie (NYSE:ABBV) reported Q2 2026 revenue of $16.99B, up 10.2%, driven by immunology and neuroscience. Skyrizi and Rinvoq revenues grew 24.4% and 24.5% respectively, offsetting Humira's 35.9% decline. However, concentration risk exists as these two products made up 47% of revenue. Oncology and aesthetics showed weaker performance, with oncology revenue down 1.5%. Adjusted EPS rose 22.9% to $3.65.

yahoo.com3 min
AUG 21
$ABBVMedAI 8/10

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

AbbVie (NYSE: ABBV) will present new clinical data on its lung cancer pipeline at the 2026 World Conference on Lung Cancer. Key data includes ABBV-1480's 90.0% ORR in squamous NSCLC and 75.9% in non-squamous NSCLC, Temab-A's Phase 1b/2 study, and ABBV-706's 82% ORR in relapsed/refractory SCLC. The company aims to advance next-generation immunotherapies and targeted ADCs.

prnewswire.com2 min
AUG 20
$ABBVMedAI 8/10

and Management Now Sees $12.7 Billion in Sales This Year

AbbVie (NYSE: ABBV) raised its neuroscience revenue guidance to $12.7 billion for 2026, up from $10.8 billion last year. Q2 neuroscience revenue grew 20.3% YoY to $3.23 billion, driven by Vraylar, therapeutic Botox, and migraine drugs Ubrelvy and Qulipta. The company is also investing in psychedelics-based medicines, acquiring bretisilocin (ABBV-2505) for up to $1.2 billion.

aol.com3 min